Advertisement
CRSP vs RXRX
Which Stock Would AI Choose? CRISPR Therapeutics AG (CRSP) vs. Recursion Pharmaceuticals (RXRX) Stock Comparison
Key Takeaways
- CRSP has shown stronger recent momentum with shares rallying over 24% in the past month, outpacing RXRX's approximately 16% gain.
- Both stocks operate in innovative biotech spaces—CRSP focuses on gene editing via CRISPR-Cas9 technology, while RXRX leverages AI for drug discovery.
- CRSP benefits from commercialization of Casgevy (exagamglogene autotemcel), its approved gene therapy for sickle cell disease, driving revenue growth.
- RXRX reports improving revenue but grapples with high cash burn and unprofitability concerns.
- Year-to-date, CRSP is up around 10%, contrasting RXRX's roughly 10% decline, highlighting divergent market positioning.
- Upcoming pipeline catalysts position CRSP for potential near-term upside, while RXRX emphasizes AI platform expansions.
Introduction
In the rapidly evolving biotech sector, CRSP and RXRX represent cutting-edge approaches to therapeutic innovation. CRISPR Therapeutics AG pioneers gene-editing technologies, while Recursion Pharmaceuticals harnesses artificial intelligence (AI) for drug discovery. This stock comparison analyzes their recent performance, business models, and market dynamics, aiding growth-oriented traders and investors navigating high-volatility biotech plays. With both firms advancing pipelines amid sector rotations, understanding relative strengths in momentum, catalysts, and risk profiles is key for informed positioning in today's market environment.
CRSP Overview and Recent Performance
CRISPR Therapeutics AG (CRSP) develops gene-editing therapies using the CRISPR-Cas9 platform, targeting serious diseases like sickle cell disease and beta thalassemia. Its lead product, Casgevy (developed with Vertex Pharmaceuticals), marks the first approved CRISPR-based therapy, generating initial revenues from recent commercial launches.
In recent market activity, CRSP shares have rallied significantly, up over 24% in the past month and nearly 13% weekly, reflecting positive sentiment around pipeline progress. Q4 2025 earnings highlighted Casgevy sales ramp-up, multiple upcoming data readouts, and a strong cash position bolstered by a $550 million convertible notes offering. Despite EPS (earnings per share) misses, investor focus on catalysts like CTX310 Phase 1 data and in vivo programs has driven outperformance versus the broader medical sector.
RXRX Overview and Recent Performance
Recursion Pharmaceuticals, Inc. (RXRX) employs an AI-powered platform to map biological relationships and accelerate drug discovery across multiple therapeutic areas. Key partnerships enhance its tech-enabled approach to identifying novel targets.
Recent weeks have seen RXRX shares post gains of about 16% monthly and 14% weekly, rebounding from prior declines amid broader biotech pressures. Q4 2025 results showed revenue beats and slight EPS improvements, supported by expansions like the Citeline partnership for AI trial data. However, ongoing cash burn and lack of profitability have tempered enthusiasm, contributing to year-to-date underperformance versus peers.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top 25 performers from its library of 351 AI trading bots, which collectively trade thousands of tickers across diverse strategies. These curated bots excel in current market conditions, boasting annualized returns ranging from +26% to +122%, win rates of 55-88%, and timeframes from 5 minutes to 60 minutes. Examples include semiconductor-focused agents with +97% returns and 68% win rates on tickers like SOXL, or multi-ticker energy bots at +81% annualized. Strategies vary from swing trading dips to double-agent pairs trading, with drawdowns managed between $2,000-$49,000. Traders can explore these high-performing, adaptive AIs tailored to volatility and trends—visit Trending AI Robots for real-time insights.
Head-to-Head Comparison
CRSP and RXRX both target biotech growth but diverge in models: CRSP’s targeted gene-editing pipeline nears revenue inflection via approved assets, contrasting RXRX’s broader AI platform still scaling discovery outputs. Growth drivers for CRSP include Casgevy uptake and near-term readouts; RXRX relies on partnerships and tech validation amid higher R&D spend.
Recent momentum favors CRSP with superior monthly gains and positive YTD returns, versus RXRX’s volatility and cash concerns. Risk profiles are elevated for both—clinical trial uncertainties, regulatory hurdles—but CRSP’s cash runway offers relative stability. Sector exposure centers on innovative therapies, yet market sentiment leans toward CRSP’s tangible catalysts over RXRX’s platform bets.
Tickeron AI Verdict
Tickeron’s AI analysis currently favors CRSP over RXRX, based on stronger trend consistency, recent outperformance, and pipeline catalysts like Casgevy momentum and data readouts. CRSP exhibits better relative positioning amid biotech rotations, with higher probability of sustained upside from commercial progress versus RXRX’s execution risks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Buy and RXRX is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRSP’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).
- CRSP’s FA Score: 0 green, 5 red.
- RXRX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRSP’s TA Score shows that 5 TA indicator(s) are bullish while RXRX’s TA Score has 2 bullish TA indicator(s).
- CRSP’s TA Score: 5 bullish, 3 bearish.
- RXRX’s TA Score: 2 bullish, 8 bearish.
Price Growth
CRSP (@Biotechnology) experienced а +3.33% price change this week, while RXRX (@Biotechnology) price change was -3.80% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +5.89%. For the same industry, the average monthly price growth was +2.09%, and the average quarterly price growth was +1952.22%.
Reported Earning Dates
CRSP is expected to report earnings on Aug 10, 2026.
RXRX is expected to report earnings on Aug 11, 2026.
Industries' Descriptions
@Biotechnology (+5.89% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| CRSP | RXRX | CRSP / RXRX | |
| Capitalization | 5.35B | 1.68B | 319% |
| EBITDA | -627.33M | -478.66M | 131% |
| Gain YTD | 3.661 | -22.616 | -16% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 1M | 65.7M | 2% |
| Total Cash | 2.44B | 654M | 373% |
| Total Debt | 788M | 72.4M | 1,088% |
CRSP | ||
|---|---|---|
OUTLOOK RATING 1..100 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 91 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 46 | |
P/E GROWTH RATING 1..100 | 73 | |
SEASONALITY SCORE 1..100 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CRSP | RXRX | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 77% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 77% | 2 days ago 81% |
| Advances ODDS (%) | 2 days ago 79% | 12 days ago 83% |
| Declines ODDS (%) | 14 days ago 83% | 7 days ago 88% |
| BollingerBands ODDS (%) | N/A | 2 days ago 88% |
| Aroon ODDS (%) | 2 days ago 86% | 2 days ago 88% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PRAE | 40.39 | 0.78 | +1.98% |
| PlanRock Alternative Growth ETF | |||
| IHD | 7.94 | 0.05 | +0.63% |
| VOYA EMERGING MARKETS HIGH Income DIVIDEND EQUITY FUND | |||
| WQTM | 37.85 | 0.02 | +0.05% |
| WisdomTree Quantum Computing Fund | |||
| IYW | 253.28 | -0.29 | -0.11% |
| iShares US Technology ETF | |||
| WDI | 13.48 | -0.07 | -0.52% |
| Western Asset Diversified Income Fund | |||
RXRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with ABCL. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then ABCL could also see price increases.
| Ticker / NAME | Correlation To RXRX | 1D Price Change % | ||
|---|---|---|---|---|
| RXRX | 100% | -2.01% | ||
| ABCL - RXRX | 60% Loosely correlated | +3.80% | ||
| ABSI - RXRX | 60% Loosely correlated | +13.50% | ||
| CRSP - RXRX | 59% Loosely correlated | +0.50% | ||
| PRME - RXRX | 58% Loosely correlated | +4.33% | ||
| BEAM - RXRX | 56% Loosely correlated | +4.07% | ||
More | ||||